Zurcher Kantonalbank Zurich Cantonalbank Has $113,000 Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Zurcher Kantonalbank Zurich Cantonalbank lessened its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 17.7% in the fourth quarter, HoldingsChannel reports. The fund owned 5,571 shares of the company’s stock after selling 1,195 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in 4D Molecular Therapeutics were worth $113,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its holdings in 4D Molecular Therapeutics by 359.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company’s stock valued at $100,000 after buying an additional 3,873 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in 4D Molecular Therapeutics in the 3rd quarter worth about $141,000. State Board of Administration of Florida Retirement System bought a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at about $142,000. Fox Run Management L.L.C. acquired a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth approximately $155,000. Finally, SG Americas Securities LLC bought a new position in shares of 4D Molecular Therapeutics during the third quarter worth approximately $156,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock in a transaction on Friday, February 16th. The shares were sold at an average price of $27.67, for a total transaction of $48,422.50. Following the transaction, the insider now owns 1,737 shares in the company, valued at $48,062.79. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 21,145 shares of company stock worth $668,951. 7.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

FDMT has been the topic of a number of analyst reports. The Goldman Sachs Group reissued a “buy” rating and set a $81.00 price target on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 7th. Barclays began coverage on 4D Molecular Therapeutics in a research note on Monday, April 15th. They issued an “overweight” rating for the company. Royal Bank of Canada increased their price objective on shares of 4D Molecular Therapeutics from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, March 1st. Finally, Jefferies Financial Group lifted their price objective on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $44.22.

4D Molecular Therapeutics Stock Down 2.6 %

NASDAQ FDMT opened at $25.64 on Friday. 4D Molecular Therapeutics, Inc. has a twelve month low of $9.44 and a twelve month high of $36.25. The business’s fifty day moving average is $28.30 and its 200 day moving average is $21.58. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -9.64 and a beta of 2.94.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.09). The firm had revenue of ($0.02) million for the quarter, compared to analyst estimates of $4.67 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 34.14%. On average, research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.03 earnings per share for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.